For the year ending 2025-12-31, TNDM made $1,014,736K in revenue. -$197,170K in net income. Net profit margin of -19.43%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Sales | 1,014,736 | |||
| Cost of sales | 468,722 | |||
| Gross profit | 546,014 | |||
| Selling, general and administrative | 444,989 | |||
| Research and development | 193,114 | |||
| Acquired in-process research and development expenses | 75,217 | |||
| Litigation and settlement expense | 19,951 | |||
| Total operating expenses | 733,271 | |||
| Operating loss | -187,257 | |||
| Interest income and other income, net | 9,086 | |||
| Interest expense | 7,907 | |||
| Loss from equity method investments | -14,194 | |||
| Loss on extinguishment of debt | 0 | |||
| Total other income (expense), net | -13,015 | |||
| Loss before income taxes | -200,272 | |||
| Income tax expense | 4,438 | |||
| Net loss | -204,710 | |||
| Unrealized gain (loss) on short-term investments | 517 | |||
| Unrealized loss on cash flow hedges | -312 | |||
| Foreign currency translation gains (losses) | 7,335 | |||
| Comprehensive loss | -197,170 | |||
| Net loss per share - basic (in dollars per share) | -3.04 | |||
| Net loss per share - diluted (in dollars per share) | -3.04 | |||
| Weighted average shares used to compute basic net loss per share (in shares) | 67,285,000 | |||
| Weighted average shares used to compute diluted net loss per share (in shares) | 67,285,000 | |||
TANDEM DIABETES CARE INC (TNDM)
TANDEM DIABETES CARE INC (TNDM)